Tavapadon
tavapadon
FILED
Drug Profile
ModalitySmall molecule
RoutePO
Therapy AreaNeurology
Peak Sales Est$1000M
Formulations[]
Mechanism: D3/D2 partial agonist
Expert: Dopamine D3-preferring partial agonist with D2 partial agonism, providing balanced dopaminergic modulation in schizophrenia/bipolar.
Everyday: Balances dopamine activity in the brain to treat psychiatric conditions.
Targets: ["D3","D2"]
Programs (1)
| Indication | Stage | Key Study | Regional Status |
|---|
| PD | FILED | TEMPO-1/2/3 | [] |
Upcoming Catalysts (1)
Tavapadon - Parkinson's - FDA Approval
Q3 2026
Notes
Selective D1/D5 partial agonist for Parkinson's disease. First-in-class. Filed after positive Phase 3 results.
Data from Supabase · Updated 2026-03-24